Insmed Incorporated Announces IPLEX(TM) Availability Nationwide For Children With Severe Short Stature

RICHMOND, Va.--(BUSINESS WIRE)--May 25, 2006--Insmed Incorporated (NASDAQ:INSM - News) announced today the nationwide availability of IPLEX(TM) (mecasermin rinfabate (rDNA origin). IPLEX was approved as an orphan drug by the Food and Drug Administration in December 2005 for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. IPLEX is the only once-daily IGF-I replacement therapy available for the treatment of severe primary IGFD.